Aelix Therapeutics

Biotechnology - Therapeutics and Diagnostics


Aelix Therapeutics is a spin off company from HIVACAT, specializing in the development of immunotherapies against HIV infection. Aelix supports the development and clinical validation of the immunogen HTI, its main product, as a therapeutic vaccine for the treatment of HIV infection. HTI has been developed within the HIVACAT program, from the AIDS Research Institute IrsiCaixa.